|
|
|
|
|
|
|
12.06.25 - 21:33
|
Demystifying Biogen: Insights From 11 Analyst Reviews (Benzinga)
|
|
|
Latest Ratings for BIIB
DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy
View More Analyst Ratings for BIIB
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
12.06.25 - 07:03
|
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity (GlobeNewswire EN)
|
|
|
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizu...
|
|
|
|
|
|
|
|
|
|
|
22.05.25 - 08:51
|
Aufschlag von 246 Prozent! Sanofi greift nach Alzheimer-Hoffnung (Der Aktionaer)
|
|
|
Trotz der Verfügbarkeit des Alzheimer-Medikaments Leqembi (Lecanemab) vom Forschungsduo Eisai respektive Biogen ist der Bedarf an Therapien zur Behandlung der Demenzform weiterhin extrem hoch. Sanofi will sich nun einen Hoffnungsträger gegen Alzheimer unter den Nagel reißen, der sich in der klinischen Entwicklungsphase befindet....
|
|
|
|
|
|
|
15.05.25 - 06:01
|
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026) (Cision)
|
|
|
Stockholm, Sweden, May 15, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding to a 73 percent growth compared to the previous year. This would generate approximately SEK 510 M in royalty to BioArctic during the same period.
Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai...
|
|
|
|
|
13.05.25 - 13:06
|
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
|
|
|
– Regulatory alignment achieved for Phase 3 EMPEROR study of zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome; Study start anticipated in 2Q 2025 –
– Zorevunersen collaboration with Biogen brings leading capabilities for commercializing high value, disease-modifying medicines for rare genetic diseases; Stoke retains full rights in the United States, Canada, and Mexico –
– As of March 31, 2025, the Company had $380.3 million in cash, cash equivalents, and marketable securities, anticipated to fund operations beyond 2H 2027 Phase 3 data and into launch readiness projected to mid-2028 –
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financ...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
